A Multi Center, Randomized, Double Blind, Placebo-controlled, Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACZ885 Administered Intravenously to Patients With Type 2 Diabetes Mellitus.
Phase of Trial: Phase II
Latest Information Update: 24 Jun 2013
At a glance
- Drugs Canakinumab (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- 31 Aug 2018 Biomarkers information updated
- 24 Jun 2013 Results presented at the 73rd Annual Scientific Sessions of the American Diabetes Association.
- 16 Mar 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.